AstraZeneca Pharma India (BOM:506820) Cash-to-Debt : 113.90 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AstraZeneca Pharma India's cash to debt ratio for the quarter that ended in Mar. 2024 was 113.90.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AstraZeneca Pharma India could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for AstraZeneca Pharma India's Cash-to-Debt or its related term are showing as below:

BOM:506820' s Cash-to-Debt Range Over the Past 10 Years
Min: 21.33 Med: 100.44 Max: No Debt
Current: 113.9

During the past 13 years, AstraZeneca Pharma India's highest Cash to Debt Ratio was No Debt. The lowest was 21.33. And the median was 100.44.

BOM:506820's Cash-to-Debt is ranked better than
88.42% of 1036 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs BOM:506820: 113.90

AstraZeneca Pharma India Cash-to-Debt Historical Data

The historical data trend for AstraZeneca Pharma India's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AstraZeneca Pharma India Cash-to-Debt Chart

AstraZeneca Pharma India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

21.33

29.02

51.96

69.40

113.90

AstraZeneca Pharma India Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															69.40	N/A	99.71	N/A	113.90

Competitive Comparison of AstraZeneca Pharma India's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Pharma India's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Cash-to-Debt falls into.

AstraZeneca Pharma India Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AstraZeneca Pharma India's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5237.195	/	(18.146	+	27.836)
	=	113.90

AstraZeneca Pharma India's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5237.195	/	(18.146	+	27.836)
	=	113.90

AstraZeneca Pharma India (BOM:506820) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AstraZeneca Pharma India Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Pharma India (BOM:506820) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » Cash-to-Debt

Traded in Other Exchanges

ASTRAZEN:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines